ORJ-001 achieved therapeutic exposure and was well tolerated in Phase 1 study, supporting company’s plans to initiate Phase 2 clinical trial in IPF patients Data from preclinical studies of ORJ-001 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results